Business Context and Reporting Period
Company: The Cigna Group (CI)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: The Cigna Group is a global health company operating through two primary segments: Evernorth Health Services (pharmacy benefit services, specialty pharmacy, and care services) and Cigna Healthcare (medical and coordinated solutions). The company serves approximately 185 million customer relationships across more than 30 markets.
Key Financial Metrics
| Metric (in millions, except per share) | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenues | $274,900 | $247,121 | +11% |
| Shareholders' Net Income | $5,957 | $3,434 | +73% |
| Diluted EPS | $22.18 | $12.12 | +83% |
| Adjusted Income from Operations | $8,014 | $7,741 | +4% |
| Operating Cash Flow | $9,601 | $10,363 | -7% |
| Total Debt | $31,463 | $31,972 | -2% |
| Cash and Short-Term Investments | $7,936 | $8,215 | -3% |
Note: Total Debt includes short-term debt ($592M) and long-term debt ($30,871M). Cash includes cash equivalents ($7,676M) and short-term investments ($257M) plus restricted cash.
Material Changes vs. Prior Period
- Divestiture of Medicare Advantage Business: On March 19, 2025, the company completed the sale of its Medicare Advantage, Medicare Part D, and related businesses to Health Care Service Corporation (HCSC) for $4.9 billion in cash proceeds. This transaction significantly reduced premiums and medical costs in the Cigna Healthcare segment.
- Revenue Growth: Total revenues increased 11% to $274.9 billion, driven primarily by a 17% increase in pharmacy revenues ($216.7 billion) due to higher utilization and customer growth in Evernorth. Premiums decreased 12% due to the HCSC divestiture.
- Profitability Surge: Shareholders' net income increased 73% to $5.96 billion. This was primarily due to the absence of a $2.7 billion impairment charge on VillageMD equity securities recorded in 2024.
- Segment Performance:
- Evernorth Health Services: Adjusted revenues grew 16% to $235.0 billion; pre-tax adjusted income increased 3% to $7.2 billion.
- Cigna Healthcare: Adjusted revenues declined 11% to $47.2 billion due to the HCSC sale; pre-tax adjusted income decreased 2% to $4.2 billion.
- Strategic Optimization Program: The company incurred $749 million in pre-tax costs related to an enterprise-wide efficiency initiative, including severance and asset impairments.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Rebate-Free Model: The company announced a transformative pharmacy benefits model to make drug discounts available upfront to customers. Cigna Healthcare will adopt this for fully insured customers in 2027, and Evernorth will make it standard for clients in 2028. Management expects short-term impacts to pre-tax adjusted income due to transition costs.
- Capital Allocation: The company repurchased 11.9 million shares for approximately $3.6 billion in 2025. It declared a quarterly dividend of $1.56 per share for Q1 2026.
- Investment Strategy: The company expects to deploy approximately $1.3 billion in capital expenditures in 2026, primarily for technology.
Key Risks and Contingencies:
- Regulatory Changes: The Consolidated Appropriations Act of 2026 includes provisions affecting PBM operations, including requirements to remit 100% of certain rebates to plan sponsors starting in 2028 and restrictions on PBM compensation linked to drug list prices in Medicare Part D.
- Health Care Costs: Profitability depends on accurately predicting and managing medical and pharmacy costs. Inflation and changes in drug pricing benchmarks could compress margins.
- Cybersecurity: The company faces ongoing risks from cyberattacks and data breaches, which could result in significant liability and reputational harm.
- Legal Proceedings: The company is subject to routine litigation and regulatory audits, including a final settlement with the FTC in February 2026 regarding PBM practices (resolved without monetary penalty).
Investor Verification Checklist
- HCSC Transaction Impact: Verify the long-term financial impact of the $4.9 billion Medicare Advantage divestiture on future premium revenue and medical cost trends.
- Rebate-Free Model Transition: Assess the timeline and cost implications of transitioning to the new rebate-free pharmacy model starting in 2027/2028.
- Investment Portfolio Valuation: Review the $19.5 billion investment portfolio, noting the net unrealized depreciation position due to interest rate fluctuations.
- Debt Maturities: Confirm the schedule of debt maturities, with $550 million due in 2026 and significant tranches maturing in 2027-2030.
- Regulatory Compliance: Monitor the implementation of the Consolidated Appropriations Act of 2026 and its effect on PBM revenue recognition and rebate sharing.